LY03017, also known as LPM-526000133, is a serotonin 5-HT<sub>2</sub> receptor antagonist which is under development for the treatment of schizophrenia and Alzheimer's psychosis. It acts specifically as a dual serotonin 5-HT<sub>2A</sub> receptor inverse agonist and serotonin 5-HT<sub>2C</sub> receptor antagonist. The drug is under development by Luye Pharma Group in China. As of December 2025, it is in phase 1 clinical trials. The chemical structure of LY03017 does not yet appear to have been disclosed.